Suppr超能文献

晚期糖尿病视网膜病变患者房水中内皮素-1 浓度升高。

Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy.

机构信息

Quantitative method, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.

Catholic Kwandong University College of Medicine, Incheon, Republic of Korea.

出版信息

PLoS One. 2022 May 11;17(5):e0268353. doi: 10.1371/journal.pone.0268353. eCollection 2022.

Abstract

PURPOSE

Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR.

METHODS

A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group.

RESULTS

Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0-21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6-2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7-3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0-20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0-21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3-4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0-7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively).

CONCLUSION

The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR.

摘要

目的

内皮素-1(ET-1)是一种强效的血管收缩剂,似乎与糖尿病性视网膜病变(DR)的发病机制有关。然而,关于 DR 患者眼内 ET-1 的研究有限。因此,我们研究了 DR 患者房水中 ET-1 的水平。

方法

本前瞻性研究共纳入 85 例患者。这些患者分为三组:晚期 DR 组包括严重非增殖性 DR 或增殖性 DR 患者,而早期 DR 组包括轻度非增殖性 DR 或中度非增殖性 DR 患者。那些接受白内障手术且无伴随眼部疾病的患者被纳入对照组。DR 患者在玻璃体腔内注射贝伐单抗(IVB)前和 1 个月后以及对照组在白内障手术时获得房水 ET-1 水平。

结果

晚期 DR 组包括 40 只眼(47.1%),早期 DR 组包括 19 只眼(22.4%),对照组(26 只眼,30.5%)。晚期 DR 组平均房水 ET-1 水平为 10.1±4.1 pg/mL(6.0-21.0 pg/mL),早期 DR 组为 1.9±0.7 pg/mL(0.6-2.8 pg/mL),对照组为 2.1±1.0 pg/mL(0.7-3.9 pg/mL)(P<0.001)。晚期 DR 组进一步分为严重非增殖性 DR(15 只眼,12.8%)和增殖性 DR(25 只眼,34.3%)。严重非增殖性 DR 患者的平均房水 ET-1 水平为 10.1±4.3 pg/mL(6.0-20.1 pg/mL),增殖性 DR 患者为 10.0±4.0 pg/mL(6.0-21.0 pg/mL)(基线时 P=0.928)。严重增殖性 DR 患者玻璃体腔内注射后 1 个月时的平均 ET-1 水平为 2.5±1.0 pg/mL(0.3-4.8 pg/mL),增殖性 DR 患者为 2.9±1.7 pg/mL(1.0-7.0 pg/mL)(P=0.443)。两组的平均房水 ET-1 水平均显著降低(分别为 P<0.001)。

结论

晚期 DR 组的平均房水 ET-1 水平明显高于早期 DR 组和对照组。晚期 DR 组玻璃体腔内注射后平均房水 ET-1 水平明显降低。基于我们的结果,未来关于 ET-1 在 DR 发病机制中的确切作用以及对干预措施的未来影响的研究将有助于 DR 的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90a5/9094525/5d765ceb294d/pone.0268353.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验